Treatment
Enfortumab Vedotin clinical trials
We’re tracking 45 recruiting studies that include Enfortumab Vedotin, each written for real people, not researchers, below.
Recruiting studies
- NCT06104618RecruitingPhase 2
Enfortumab vedotin for advanced penile cancer
This trial tests a drug called enfortumab vedotin for people with advanced penile cancer (squamous cell carcinoma) that has spread or cannot be surgically removed. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Phoenix, ArizonaAges 18 years+ - NCT06764095RecruitingPhase 4
Drug combo before bladder or ureter surgery for advanced cancer
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
Rochester, MinnesotaAges 18 years+ - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT03547973RecruitingPhase 2
Study of sacituzumab govitecan for advanced or non-removable bladder cancer
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
Tucson, ArizonaAges 18 years+ - NCT07720284RecruitingPhase 3
Testing new drugs for high-risk bladder cancer after surgery
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
Hot Springs, ArkansasAges 18 years+ - NCT07139977RecruitingPhase 2
Study of EV for recurrent endometrial cancer
This trial tests a drug called EV for people with recurrent endometrial cancer that has gotten worse after treatment. It may help if your cancer cells have a specific protein called nectin-4.
Milwaukee, WisconsinAges 18 years+ - NCT05614739RecruitingPhase 1
Study drug for cancers with an FGFR3 gene change
This Phase 1 trial tests LOXO-435 in people with solid tumors that have an FGFR3 pathway gene alteration. It may help shrink or control cancer by targeting this specific gene change.
Tucson, ArizonaAges 18 years+ - NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06011954Recruiting
Study of PADCEV in adults with cancer in South Korea
This study observes adults in South Korea who are already being treated with PADCEV injections for cancer. It helps doctors gather real-world information about how the drug works and how people respond to it.
Goyang-si, Gyeonggi-doAges Any age - NCT06145308RecruitingPhase 2
Precision treatment for salivary gland cancer
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Beijing, Beijing MunicipalityAges 18–100 - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Duarte, CaliforniaAges 18 years+ - NCT06493552RecruitingPhase 2/Phase 3
Testing sEphB4-HSA in EphrinB2-high bladder cancer
This trial tests a new drug called sEphB4-HSA for people with a specific type of bladder cancer (urothelial carcinoma) that has high levels of a protein called EphrinB2. The study aims to see if this drug can shrink tumors or prevent them from growing, and it compares it to standard treatments like chemotherapy or immunotherapy.
Santa Monica, CaliforniaAges 18 years+ - NCT06657157Recruiting
Nerve side effects study for new bladder cancer treatment
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
Augsburg, BavariaAges 18 years+ - NCT06724159Recruiting
Study of funded drugs for genitourinary cancers
This study looks at how well newer funded cancer drugs work for people with cancers of the urinary or reproductive systems, such as bladder, prostate, or kidney cancer. Researchers want to learn about real-world outcomes based on routine care in hospitals across Spain.
Albacete, AlbaceteAges 18 years+ - NCT07043972RecruitingPhase 2
Gemcitabine and carboplatin after EV-pembrolizumab for bladder cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07183319RecruitingPhase 2
ctDNA test in advanced bladder cancer
This trial studies how a blood test that looks for tumor DNA (ctDNA) can help guide treatment in people with advanced bladder cancer that cannot be removed by surgery or has spread. It aims to see if the test results can help doctors choose the best therapy.
Oklahoma City, OklahomaAges 18 years+ - NCT07232602RecruitingPhase 1/Phase 2
New drug combinations for advanced bladder cancer
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
San Francisco, CaliforniaAges 18 years+ - NCT07287995RecruitingPhase 1/Phase 2
Study of ASP2998 alone or with other therapies for solid tumors
This trial tests a new drug, ASP2998, given alone or with standard cancer treatments for people with advanced solid tumors, including certain types of lung, bladder, stomach, and breast cancers. The goal is to see if ASP2998 can help when other treatments have stopped working or are not an option.
Hackensack, New JerseyAges 18 years+ - NCT07390617Recruiting
Nerve damage from enfortumab vedotin in bladder cancer
This study looks at how enfortumab vedotin, a cancer drug, affects the nerves. It aims to understand and track neuropathy (nerve damage) in people with urothelial carcinoma, so doctors can better manage side effects.
Basking Ridge, New JerseyAges 18 years+ - NCT07647289RecruitingPhase 2
Immunotherapy plus chemotherapy before bladder cancer surgery
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
Beijing, Beijing MunicipalityAges 18–80 - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+
Common questions
- Are there clinical trials studying Enfortumab Vedotin?
- Yes. Clin2 currently lists 45 recruiting studies that include Enfortumab Vedotin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Enfortumab Vedotin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Enfortumab Vedotin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Enfortumab Vedotin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.